Psoriasis: Rationale for targeting interleukin-17

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 717-724

  Girolomoni, G ^a   Mrowietz, U ^b   Paul, C ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; BRODALUMAB; CALGRANULIN A; CALGRANULIN B; CHEMOKINE RECEPTOR CCR6; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ETANERCEPT; FILAGGRIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 12P40; INTERLEUKIN 14; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 6; INTERLEUKIN 8; IXEKIZUMAB; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PSORIASIN; SECUKINUMAB; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ASTHMA; CD4+ T LYMPHOCYTE; CELL MIGRATION; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INNATE IMMUNITY; KERATINOCYTE; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAST CELL; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-17; MODELS, THEORETICAL; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866992632     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11099.x     Document Type: Review

References (78)

1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537-41.
2. Schäfer T,. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006; 212: 327-37.
3. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-24.
4. de Korte J, Sprangers MA, Mombers FM, Bos JD,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-7.
5. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
6. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-8.
7. Lynde CW, Poulin Y, Guenther L, Jackson C,. The burden of psoriasis in Canada: insights from the psoriasis knowledge in Canada (SKIN) survey. J Cutan Med Surg 2009; 13: 235-52.
8. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-82.
9. Gourraud PA, Le Gall C, Puzenat E, et al. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision on psoriasis. J Invest Dermatol 2012; 132: 2171-5.
10. Mrowietz U, Elder JT, Barker J,. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-19.
11. Gerdes S, Mrowietz U,. Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 2009; 38: 21-36.
12. Gisondi P, Girolomoni G,. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-24.
13. Prey S, Paul C, Bronsard V, et al. Assessment of the risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 31-5.
14. Lee S, Mendelsohn A, Sarnes E,. The burden of psoriatic arthritis. A literature review from a global health systems perspective. P T 2010; 35: 680-9.
15. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2008; 55: 829-35.
16. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5.
17. Gisondi P, Farina S, Giordano MV, Girolomoni G,. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754-7.
18. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
19. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
20. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
21. Roberson EDO, Bowcock AM,. Psoriasis genetics: breaking the barrier. Trends Genet 2010; 26: 415-23.
22. Farber EM, Nall ML, Watson W,. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974; 109: 207-11.
23. Brandrup F, Hauge M, Henningsen K, Eriksen B,. Psoriasis in an unselected series of twins. Arch Dermatol 1978; 114: 874-8.
24. Nestle FO, Kaplan DH, Barker J,. Psoriasis N Engl J Med 2009; 361: 496-509.
25. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827-51.
26. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
27. Cargill M, Schrodi SJ, Chang M, et al. A large-scale association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90.
28. Nair RP, Duffin KC, Helms C, et al. Genomewide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 2009; 41: 199-204.
29. Ellinghaus E, Ellinghaus D, Start D, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42: 991-5.
30. Bohm B, Burkhardt H, Uebe S, et al. Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization. Arthritis Res Ther 2012; 14: R84.
31. Albanesi C, De Pità O, Girolomoni G,. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007; 25: 581-8.
32. Monteleone G, Pallone F, MacDonald TT, et al. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond) 2011; 120: 1-11.
33. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-11.
34. Ortega C, Fernández AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86: 435-43.
35. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-85.
36. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
37. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009; 15: 1013-15.
38. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ,. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-91.
39. Büchau AS, Gallo RL,. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007; 25: 616-24.
40. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
41. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-41.
42. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-41.
43. Miossec P, Korn T, Kuchroo VK,. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
44. Gaffen SL,. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-67.
45. Pappu R, Ramirez-Carrozzi V, Ota N, et al. The IL-17 family cytokines in immunity and disease. J Clin Immunol 2010; 30: 185-95.
46. Moseley TA, Haudenschild DR, Rose L, Reddi AH,. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-74.
47. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9.
48. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-102.
49. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C,. IL-17 and IL-22: siblings, not twins. Trends Immunol 2010; 31: 354-61.
50. Iwakura Y, Ishigame H, Saijo S, Nakae S,. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-62.
51. Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009; 182: 5296-305.
52. Huber M, Heink S, Grothe H, et al. A Th17-like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity. Eur J Immunol 2009; 39: 1716-25.
53. Laggner U, Di Meglio P, Perera G, et al. Identification of a novel pro-inflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 2011; 187: 2783-93.
54. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187: 490-500.
55. Pène J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008; 180: 7423-30.
56. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
57. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164: 6621-32.
58. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129: 2175-83.
59. Albanesi C, Cavani A, Girolomoni G,. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes. Synergistic or antagonist effects with IFN-γ and TNF-α. J Immunol 1999; 162: 494-502.
60. Carrier Y, Ma H-L, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011; 131: 2428-37.
61. Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012; 21: 104-10.
62. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-603.
63. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-83.
64. Chen S, Crother TR, Arditi M,. Emerging role of IL-17 in atherosclerosis. J Innate Immun 2010; 2: 325-33.
65. von Vietinghoff S, Ley K,. Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 2010; 21: 463-9.
66. Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011; 106: 125-34.
67. de Boer O, van der Meer J, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010; 220: 499-508.
68. Butcher M, Galkina E,. Current views on the functions of IL-17-producing cells in atherosclerosis. Thromb Haemost 2011; 106: 787-95.
69. Singh TP, Schön MP, Wallbrecht K, et al. 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184: 7257-67.
70. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011; 186: 1495-502.
71. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124: 1022-10, e1- 395.
72. Ye P, Garvey P, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001; 25: 335-40.
73. Cua D, Tato C,. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10: 479-89.
74. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65-8.
75. Genovese MC, van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 929-39.
76. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
77. Garber K,. Psoriasis: from bed to bench and back. Nat Biotechnol 2011; 29: 563-6.
78. Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-98.